59 results
Keyword Beovu Remove keyword
-
List item
Direct healthcare professional communication (DHPC): Beovu ® (brolucizumab): Updated recommendations to minimise the known risk of intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion
Active substance: Brolucizumab, DHPC type: Type II variation, Last updated: 05/11/2021Beovu ® (brolucizumab): Updated … Beovu ® (brolucizumab): Updated … Communication XX Oct, 2021 Beovu ® (brolucizumab): Updated … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Beovu, Brolucizumab
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Ophthalmology
PIP number: EMEA-002691-PIP02-20, Route(s) of administration: Intravitreal use, Pharmaceutical form(s): Solution for injection
Decision date: 23/10/2020, Last updated: 22/07/2021, Compliance check: XInvented name Beovu Active substance Brolucizumab … waiver for brolucizumab (Beovu), (EMEA-002691-PIP02-20 … waiver for brolucizumab (Beovu), (EMEA-002691-PIP02-20 … -
List item
Human medicine European public assessment report (EPAR): Beovu (updated)
brolucizumab, Wet Macular Degeneration
Date of authorisation: 13/02/2020,
, Revision: 10, Authorised, Last updated: 13/09/2023
Beovu Eye Diseases Retinal Diseases Retinal … orised brolucizumab Overview Beovu is a medicine used to treat … recognising faces. In adults, Beovu is used to treat: • the … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019
CHMP, Last updated: 13/12/2019Beovu … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022
CHMP, Last updated: 25/02/2022Beovu … -
List item
Human medicine European public assessment report (EPAR): Vabysmo
Faricimab, Wet Macular Degeneration; Macular Edema; Diabetes Complications
Date of authorisation: 15/09/2022,, Revision: 1, Authorised, Last updated: 19/07/2023
-
List item
Human medicine European public assessment report (EPAR): Ipique
bevacizumab, Wet Macular Degeneration
Date of refusal: 29/04/2022, Refused, Last updated: 24/05/2022 -
List item
Withdrawn application: Susvimo
ranibizumab, date of withdrawal: 02/05/2023, Initial authorisation, Last updated: 18/07/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 10-12 May 2023 (updated)
European Medicines Agency, Amsterdam, the Netherlands, from 10/05/2023 to 12/05/2023, Last updated: 31/08/2023 -
List item
List of medicines under additional monitoring (updated)
Last updated: 26/09/2023 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 - 12 May 2023
PRAC, Last updated: 22/05/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 22-25 May 2023
European Medicines Agency, Amsterdam, the Netherlands, from 22/05/2023 to 25/05/2023, Last updated: 22/05/2023 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 25/09/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 13-16 March 2023
European Medicines Agency, Amsterdam, the Netherlands, from 13/03/2023 to 16/03/2023, Last updated: 22/06/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 24-27 October 2022
European Medicines Agency, Amsterdam, the Netherlands, from 24/10/2022 to 27/10/2022, Last updated: 31/03/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 27-30 March 2023
European Medicines Agency, Amsterdam, the Netherlands, from 27/03/2023 to 30/03/2023, Last updated: 22/05/2023 -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 11/09/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 2-5 May 2022
European Medicines Agency, Amsterdam, the Netherlands, from 02/05/2022 to 05/05/2022, Last updated: 06/02/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 25-28 October 2021
European Medicines Agency, Amsterdam, the Netherlands, from 25/10/2021 to 28/10/2021, Last updated: 02/08/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 7-10 November 2022
European Medicines Agency, Amsterdam, the Netherlands, from 07/11/2022 to 10/11/2022, Last updated: 10/01/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 February 2022
European Medicines Agency, Amsterdam, the Netherlands, from 07/02/2022 to 10/02/2022, Last updated: 07/11/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 8-11 November 2021
Online, from 08/11/2021 to 11/11/2021, Last updated: 20/01/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 23-26 January 2023
European Medicines Agency, Amsterdam, the Netherlands, from 23/01/2023 to 26/01/2023, Last updated: 14/04/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 11-14 October 2021
European Medicines Agency, Amsterdam, the Netherlands, from 11/10/2021 to 14/10/2021, Last updated: 20/01/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 June 2021
European Medicines Agency, Amsterdam, the Netherlands, from 07/06/2021 to 10/06/2021, Last updated: 07/06/2021